FDA指导原则:pCR作为高风险早期乳腺癌新辅助治疗终点加速药物研发

2021-10-01 美国食品和药品监督管理局 FDA

FDA指导原则:pCR作为高风险早期乳腺癌新辅助治疗终点加速药物研发

中文标题:

FDA指导原则:pCR作为高风险早期乳腺癌新辅助治疗终点加速药物研发

英文标题:

Pathological Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer: Use as an Endpoint to Support Accelerated Approval

发布日期:

2021-10-01

简要介绍:

FDA指导原则:pCR作为高风险早期乳腺癌新辅助治疗终点加速药物研发

相关资料下载:
[AttachmentFileName(sort=1, fileName=1.pdf)] GetToolGuiderByIdResponse(projectId=1, id=3fdf91c002222a63, title=FDA指导原则:pCR作为高风险早期乳腺癌新辅助治疗终点加速药物研发, enTitle=Pathological Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer: Use as an Endpoint to Support Accelerated Approval, guiderFrom=FDA, authorId=0, author=, summary=FDA指导原则:pCR作为高风险早期乳腺癌新辅助治疗终点加速药物研发, cover=, journalId=0, articlesId=null, associationId=486, associationName=美国食品和药品监督管理局, associationIntro=美国食品和药品监督管理局是美国公共卫生及服务部的一个代理商,其由委员会办公室和4个监督核心功能理事机构组成。, copyright=0, guiderPublishedTime=Fri Oct 01 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p>FDA指导原则:pCR作为高风险早期乳腺癌新辅助治疗终点加速药物研发</p>, tagList=[TagDto(tagId=285, tagName=乳腺癌)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=89, categoryName=乳腺癌, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指导原则, guiderLanguage=1, guiderRegion=6, opened=0, paymentType=, paymentAmount=2, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=37298, appHits=31, showAppHits=0, pcHits=338, showPcHits=37267, likes=0, shares=4, comments=1, approvalStatus=1, publishedTime=Thu Oct 21 18:29:45 CST 2021, publishedTimeString=2021-10-01, pcVisible=1, appVisible=1, editorId=1614372, editor=MedSciZeng, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=小小医者, createdTime=Thu Oct 21 18:26:12 CST 2021, updatedBy=1614372, updatedName=MedSciZeng, updatedTime=Sat Jan 06 19:36:10 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=1.pdf)])
1.pdf
下载请点击:
评论区 (1)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1079013, encodeId=4b6e10e90137b, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d81e2801105, createdName=1020235510, createdTime=Sat Dec 11 10:53:38 CST 2021, time=2021-12-11, status=1, ipAttribution=)]
    2021-12-11 1020235510

    学习

    0